5/9/2025

Standout this past week was Disney. Internet commerce earnings.

Source: SeekingAlpha

5/9/2025

Novo Nordisk's stock has plummeted over 60%, while also arguably losing market share to Eli Lilly. Click here to find out why NVO stock is a Buy.

Source: SeekingAlpha

5/9/2025

Metsera is a new GLP-1 player with a Phase 2b injectable and promising oral and amylin drugs in development. Learn why MTSR stock is a hold.

Source: SeekingAlpha

5/9/2025

Invesco International Diversified Fund offers investors broad-based exposure to non-US equities by combining 4 portfolios that varied individual mandates regarding region & company size.

Source: SeekingAlpha

5/9/2025

Our actively managed, bottom-up stock selection drives the fund’s sector, country and regional allocations.

Source: SeekingAlpha

5/8/2025

Hims & Hers achieved 136% YoY subscriber growth and unveiled ambitious 2030 goals. Discover how precision medicine drives their best quarter yet.

Source: SeekingAlpha

5/8/2025

Our actively managed, bottom-up stock selection drives the fund’s sector and country allocations.

Source: SeekingAlpha

5/7/2025

Novo Nordisk A/S (NVO) Q1 2025 Results Conference Call May 7, 2025 7:00 AM ETCompany ParticipantsJacob Rode - Head of Investor RelationsLars Jorgensen -...

Source: SeekingAlpha

5/7/2025

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more about NVO stock here.

Source: SeekingAlpha

5/7/2025

Hims & Hers Health sees strong Q1 results and expanded EBITDA guidance, but high short interest drives May 6 rally. Click here to read why HIMS stock is a Hold.

Source: SeekingAlpha

5/7/2025

Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO stock remains a strong buy for me.

Source: SeekingAlpha

5/6/2025

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click for my updated look at HIMS stock.

Source: SeekingAlpha

5/6/2025

Source: SeekingAlpha

5/6/2025

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, competition, and growth sustainability.

Source: SeekingAlpha

5/6/2025

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at AMGN stock after its Q1 earnings.

Source: SeekingAlpha

5/4/2025

The Oracle of Omaha will cede the helm of Berkshire Hathaway. (0:17) The Fed is expected to hold rates steady this week. (3:03) Is this the start of a new bear market?

Source: SeekingAlpha

5/3/2025

Marquee earnings releases this week include AMD, F, PLTR & NVO. Stay ahead of the market with Seeking Alpha's Wall Street Week Ahead newsletter.

Source: SeekingAlpha

5/3/2025

LLY's post-market drop offers investment potential with robust R&D, capex strategies, and strong cash flow, positioning it for growth amidst headwinds. Read more on LLY stock here.

Source: SeekingAlpha

5/3/2025

Eli Lilly’s expanding US production and advancing pipeline offset near-term headwinds and support bullish conviction. Read why LLY stock is a buy.

Source: SeekingAlpha

5/3/2025

Boost your investments with a 4-Factor Dividend Growth Strategy. Learn how this growth-focused approach outperforms benchmarks with a 14.42% CAGR. See more on SCHD.

Source: SeekingAlpha